



Immedica gains the right to anti-tumor agent Yondelis® in the United Kingdom

Immedica is pleased to announce that from 1 September 2018, it has become the exclusive distributor for the innovative anti-cancer drug Yondelis® in the United Kingdom. Yondelis® is an established treatment for patients suffering from soft tissue sarcomas (STS) and platinum sensitive ovarian cancer. "I believe Immedica will fill an important role as a facilitator for making Yondelis® available for patients in the United Kingdom", says Anders Edvell, CEO of Immedica.

About YONDELIS® (trabectedin)

YONDELIS® (trabectedin) is a multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, *Ecteinascidia turbinata*. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair. It is approved in close to 80 countries in North America, Europe, South America and Asia for the treatment of advanced soft tissue sarcomas as a single-agent and for relapsed ovarian cancer in combination with DOXIL®/CAELYX® (doxorubicin HCl liposome injection) in the European Union. Under a licensing agreement with PharmaMar, Janssen Products, L.P. has the rights to develop and sell YONDELIS® globally except in Europe, where PharmaMar holds the rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceuticals.

About Immedica

Immedica is a fast-growing private European niche pharma company. The company is based in Stockholm, Sweden, and has a pan-European commercial coverage with the Nordics as its stronghold. Immedica provides significant know-how and experience from commercialization of niche/specialty care products across the European and Middle East territories, and the company's management team has an outstanding track record of operating niche pharma products in Europe. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, and product distribution. Today, Immedica manage many of its products via operations at Medical Need Europe, a niche/orphan pharma company recently acquired. Immedica's main owner is Impilo AB, a private Swedish Health Care investment company established in 2017, and with more than SEK 3.5 bn in capital from leading Nordic and international investors. More information is available at www.immedica.com or www.medicalneed.com

For more information: Anders Edvell, CEO, Immedica anders.edvell@immedica.com +46 705 44 61 26